CRVO CervoMed Inc.
Company Analysis
Latest News
CervoMed Posts Q2 Results and Banks on a Partner to Reach the Finish Line — But Will Anyone Bite?
Shares of CervoMed jumped 7.3% to $3.07 after the clinical-stage biotech reported second-quarter 2026 results that gave investors what they most needed: more...
🟢 CervoMed is trading 7.3% up in after-hours trading after extending cash runway through Q3 2027
CervoMed is trading at $3.07 (+7.34%) after reporting second-quarter 2026 results and corporate updates. • Cash runway extends through Q3 2027, supported by...
🔴 CervoMed is trading 5.2% down today with no confirmed catalyst identified
CervoMed is trading at $2.72, down 5.23%, with no confirmed catalyst identified. - No new company-specific announcement dated August 7–10 was identified; the...
🟢 CervoMed is trading 5% up today after neflamapimod’s UK Innovation Passport designation
CervoMed is trading 5.34% up now at $2.96 after neflamapimod received an Innovation Passport designation under the UK’s Innovative Licensing and Access Pathway...
CervoMed's Neflamapimod Granted UK Innovation Passport for Dementia with Lewy Bodies
CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been awarded an Innovation Passport designation in the United Kingdom. This designation...
🟢 CervoMed is trading 5.8% up today amid a broader market rally
CervoMed is trading at $2.75 (5.8% up), extending its recent rebound from late-July lows amid a broader risk-on market environment. • The upward move appears...
🔴 CervoMed is trading 6.4% down today amid broader small-cap biotech volatility
CervoMed is trading at $2.49, down 6.4% today, amid a lack of fresh company-specific news or filings to explain the downward move. • The decline follows a...
🟢 CervoMed is trading 5.3% up today amid a broader market rebound
CervoMed is trading 5.3% higher at $2.80 in pre-market action, likely tracking a broader market rebound as major indices rise. • The stock is up from its...
🟢 CervoMed is trading 6.5% up today as it recovers from a biotech selloff following recent trial and IP progress
CervoMed is trading at $2.97 (up 6.5%) in pre-market, recovering part of last week’s steep biotech selloff as investors weigh recent clinical and regulatory...